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The prevalence rate of cardiovascular disease is higher for males than females, and estradiol (E2) induces
AMP-activated protein kinase (AMPK) activation, which is known to regulate proliferation of VSMC. We
identiﬁed the estrogenic properties of nordihydroguaiaretic acid (NDGA, a lignan phytoestrogen) that
inhibit VSMC proliferation and explored the underlying mechanisms. Both the phosphorylation and
expression of LKB1 were increased by NDGA. In addition, NDGA signiﬁcantly attenuated angiotensin II
(Ang II)-induced VSMC proliferation. To elucidate the estrogenic effects, we conﬁrmed that NDGA
increased estrogen receptor a (ERa) expression, similar to treatment with E2 and estriol (E3). Further-
more, tamoxifen and ERa siRNA obstructed the effects of NDGA including ERa expression, AMPK
phosphorylation and both LKB1 phosphorylation and expression. VSMC proliferation was restored by
tamoxifen and ERa siRNA. LKB1 siRNA also reversed the NDGA-mediated inhibition of VSMC prolifera-
tion. The estrogenic activity of NDGA induced LKB1 translocation from nucleus to cytosol, and tamoxifen
obstructed LKB1 translocation. The absence of LKB1 completely abolished the increase of ERa expression
induced by NDGA. Taken together, the beneﬁcial effects of estrogenic compound (E2 and NDGA) on
inhibition of VSMC proliferation are mediated by interaction between LKB1 and ERa, suggesting a po-
tential mechanism for females having less cardiovascular disease.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Abnormal proliferation of vascular smoothmuscle cell (VSMC) is
a crucial factor in the progression of atherosclerosis (1). Animal and
human studies indicate that estrogens are protective against cor-
onary atherosclerosis (2). Epidemiological studies have shown that
cardiovascular disease (CVD) is lower among premenopausal
women than inmen of the same age or in post-menopausal women
(3,4). Although the speciﬁc mechanisms by which female gender is
vasoprotective are not fully identiﬁed, reduced protective effectology, College of Medicine,
, Daegu, 42415, Republic of
rmacological Society.
work.
g by Elsevier B.V. on behalf of Japa
d/4.0/).against CVD in postmenopausal woman is considered to be due to
the endogenous estrogen depletion (5).
According to recent articles, estrogen inhibits DNA synthesis of
vascular cells and has antiproliferative and vasodilation effects in
VSMCs (6, 7). Two classical estrogen receptor subtypes, ERa and
ERb, both of which are members of the super family of steroid
hormone receptors. Our analysis suggest that nordihydroguaiaretic
acid (NDGA, a lignan phytoestrogen) has positive connection with
estradiol (E2). The connection is supported by recent studies
(8e11), where NDGA has been shown to have estrogenic activity.
NDGA, extracted from chaparral (Larrea tridentata Coville), has
many beneﬁcial bioactivities such as antioxidant, anticancer and
cardiovascular protection and below the concentration of 10 mg/ml,
NDGA is known to has no visible cytotoxic effect on endothelial
cells (12).
AMP-activated protein kinase (AMPK) is a crucial factor for
maintaining cellular energy homeostasis (13,14). AMPK not onlynese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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elicits vasoprotective effects mediated by E2 (15). Moreover, AMPK
is phosphorylated by NDGA, which protects against high fat diet-
induced fatty liver (16). E2 is reported to activate AMPK through
ERa by direct interaction with the bg-binding domain of AMPKa
(17).
Several kinases acting upstream of AMPK have been identiﬁed,
including liver kinase B1 (LKB1) and Ca2þ/calmodulin-dependent
protein kinase kinase b (CaMKKb), which can activate AMPK by
phosphorylating the a-subunit at Thr172 (18,19). LKB1 has been
correlated with estrogen in various studies. In adipocytes, LKB1
expression is increased by estrogen because LKB1 has a possible
estrogen response element (ERE) site in its promoter region (20).
Furthermore, LKB1 binds to ERa in MCF-7, and LKB1 catalytic ac-
tivity enhances ERa signaling (21). These studies suggest that LKB1
and ERa may be functionally linked.
Based on these reports, we hypothesized that AMPK is activated
through the interaction between LKB1 and ERa, which is the reason
for the low cardiovascular disease in women. Therefore, we inves-
tigated whether the therapeutic effects of a phytoestrogen, NDGA,
could suppresses VSMC proliferation through the LKB1-ERa
dependent mechanism.
2. Materials and methods
2.1. Reagents and antibodies
Dulbecco's modiﬁed eagle medium (DMEM) and fetal bovine
serum (FBS) were obtained from Hyclone (Logan, UT, USA). Nordi-
hydroguaiaretic acid (NDGA), 5a-androstan-17b-ol-3-one (5a-
DHT), estriol and anti-b-actin antibody were obtained from Sig-
maeAldrich (St. Louis, MO, USA). Tamoxifen was purchased from
Cayman Chemical (Ann Arbor, MI, USA). b-Estradiol was purchased
from Tocris Bioscience (Minneapolis, MN, USA). Angiotensin II was
obtained from Calbiochem (La Jolla, CA, USA). LKB1 and ERa siRNAs,
anti-ERa and anti-p27 antibodies were obtained from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA, USA). Anti-LKB1, anti-phospho-
LKB1, anti-AMPK, anti-phospho-AMPK, anti-ACC, anti-phospho-
ACC, anti-p53 and anti-p21 antibodies were obtained from Cell
Signaling Technology (Beverly, MA, USA). The enhanced chem-
iluminescence (ECL) plus western blot detection reagent was ob-
tained from GE Healthcare (Piscataway, NJ, USA). Lipofectamine
2000 and H2DCFDA were purchased from Invitrogen (Carlsbad, CA,
USA).
2.2. Cell culture
SpragueeDawley rats (SD rats) were anesthetized with pento-
barbital (50 mg/kg). VSMCs were isolated from the thoracic aorta.
The cells were processed using a 1 mm chop setting in a 10 cm
culture dish, and cultured with 50% FBS-Dulbecco's modiﬁed ea-
gle's medium (DMEM) with 1% antibiotics in a CO2 incubator (5%
CO2/95% air, 37 C). Aortic VSMCs were maintained in DMEM with
10% FBS and 1% antibiotic-antimycotic (penicillin 10,000 U/ml,
amphotericin B 25 mg/ml, streptomycin 10,000 mg/ml). We used
VSMCs from passages 5 to 8 at 70e90% conﬂuence in 10 cm dishes,
and cell growth was arrested by incubation of the cells in serum-
free DMEM for 24 h prior to use. A549 cells were incubated in F-
12K medium with 10% FBS.
2.3. Transfection of siRNA
Aliquots of 1  104 cells were plated in 6- or 12-well plates on
the day before transfection and grown to about 60% conﬂuence.
Then, VSMCs were transfected with LKB1 and ERa siRNA usingLipofectamine 2000 and incubated in Opti-MEM® I reduced serum
medium (Invitrogen) for 4e6 h. The medium was then replaced
with DMEM containing 10% FBS. Following an incubation period of
48 h, the protein levels weremeasured bywestern blot analysis and
viability by MTT assay.
2.4. Western blot analysis
Whole cell extracts were prepared by lysing the cells in pro-prep
protein extract buffer. The protein concentration was quantiﬁed
with protein assay reagent from Bio-Rad (Hercules, CA, USA). Equal
amounts of protein were mixed with Laemmli Sample Buffer (Bio-
Rad) and heated for 5 min at 100 C before loading. Total protein
samples (30 mg) were subjected to 10% SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) for 1 h 30 min at 100e120 V. The
separated proteins were electrophoretically transferred onto PVDF
membranes for 1 h 20min at 100 V using SD Semi-dry Transfer Cell.
The membranes were blocked with 5% non-fat milk in PBS con-
taining 0.05% Tween 20 (PBS-T) for 1 h at room temperature. The
membranes were then incubated with the primary antibodies at a
dilution of 1:1000 in PBST overnight at 4 C. The membranes were
then washed with four changes of wash buffer (0.05% Tween 20 in
PBS) and incubated for 1 h at room temperature in PBS containing
anti-rabbit (Stress-gen, Ann Arbor, MI, USA) or anti-mouse IgG
(Sigma, St. Louis, MO, USA) antibodies. Finally, after three more
rinses with wash buffer, the membranes were exposed to ECL and
ECL Plus western blot analysis detection reagents.
2.5. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
analysis
Cell proliferation was analyzed using the 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay. VSMCs were seeded on 12-well plates at 1  104 cells per
well in DMEM supplemented with 10% FBS. After treatment with
various compounds, 50 ml of 1 mg/ml MTT solution was added to
each well (0.1 mg/well) and incubated for 2e4 h. The supernatants
were aspirated and the formazan crystals in each well were solu-
bilized with 200 ml dimethyl sulfoxide. An aliquot of this solution
(100 ml) was placed in the 96-well plates. Cell proliferation was
assessed by measuring the absorbance at 570 nm using a micro-
plate reader.
2.6. Flow cytometric analysis for cell cycle
VSMCs were treated with or without NDGA for 12 h. Cells
(1  104) were harvested and ﬁxed in 95% ethanol overnight. Fixed
cells were stained with propidium iodide (PI) (50 mg/ml) for
30 min at 37 C. PI enters the cells and stains the nucleus. PI stained
cells were ﬁltered using a 5 ml polystyrene round bottom tubewith
a cell-strainer cap prior to ﬂow cytometry. All ﬂow cytometry
measurements were done using a FACS Canto (Becton Dickinson,
San Jose, CA, USA). Cell cycle analysis was performed using Cell-
Quest pro-software.
2.7. Immunoﬂuorescent analysis
Cells were seeded on coverslips in 35-mm dishes, ﬁxed in 4%
formaldehyde, and permeabilized with 0.2% Triton X-100. LKB1
(Upstate, Billerica, MA, USA) and ERa primary antibodies were used
at 1:100 and incubated with cells overnight at 4 C. Rabbit FITC
secondary antibody (Molecular Probes, Eugene, OR, USA) was used
at 1:200 and incubated with cells for 1 h at room temperature. To
stain nuclei, To-pro-3 iodide (Invitrogen, Carlsbad, CA, USA) was
used at 1:200 and incubated for 10 min at room temperature. Fixed
S.A. Kim et al. / Journal of Pharmacological Sciences 132 (2016) 78e8580and immunoﬂuorescently stained cells were imaged with a Leica
confocal microscope (Bannockburn, IL, USA).
2.8. Colony formation assay
To measure colony formation, exponentially growing cells were
seeded in 6-well plates at 3  105 cells/mL. After incubation at
37 C, cells were stained with 0.5% (W/N) crystal violet. Colonies,
deﬁned as cell groups containing a minimum of 50 cells, were
assessed by measuring the absorbance at 540 nm using a micro-
plate reader.
2.9. Statistical evaluation
Results are expressed as mean ± SEM from at least three inde-
pendent experiments. Differences between data sets were assessed
by one-way analysis of variance (ANOVA) and Bonferroni's test. All
differences were considered signiﬁcant when p < 0.05.
3. Results
3.1. Estrogenic compound (NDGA) increases AMPK and LKB1
phosphorylation and ERa expression in VSMCs
In a previous report, estrogen has been shown to activate AMPK
(22), by yet an unknown mechanism. We focused our experiments
on estrogenic compound such as NDGA. We found that estrogenic
compound stimulated AMPK through LKB1 pathway. NDGA (5, 15,
25 mM) for 1 h produced a dose-dependent increase in phosphor-
ylation of LKB1 at Ser428 and of AMPK at Thr172 in VSMCs. Inter-
estingly, NDGA increased both LKB1 phosphorylation and LKB1
expression but AMPK expressionwas not altered. In addition, NDGA
increased ERa expression and levels of phospho-ACC, a major
molecule downstream of AMPK (Fig. 1A). AMPK and LKB1 wereFig. 1. Effect of estrogenic compound (NDGA) on LKB1 and AMPK phosphorylation and ERa
Ser428 (p-LKB1), LKB1 expression and ERa expression were determined by Western blot and
(0, 5, 15 and 25 mM) for 1 h (B) VSMCs were incubated with 25 mM NDGA for different time
LKB1 and ERa. Values are means ± S.E.M from 5 independent measurements. *p < 0.05 vefully phosphorylated at 1 h and this was maintained until 12 h
(Fig. 1B). NDGA also elevated LKB1 and ERa expression at 1 h
(Fig. 1B). We also carried out densitometry for the LKB1 and ERa,
expressed as a ratio to b-actin (Fig. 1C and D). These results indicate
that NDGA activates AMPK phosphorylation through LKB1 and in-
creases ERa protein expression.
3.2. Estrogenic compounds regulate LKB1 expression mediated by
ERa
To determine whether the estrogenic effects of NDGA regulate
LKB1 and AMPK, we treated cells with E2, E3 and DHT. As shown in
Fig. 2A, ERa and LKB1 expression increased in the presence of E2
and E3. Phosphorylation of both LKB1 (Ser428) and AMPK (Thr172)
also increased, as with NDGA treatment. In the case of DHT, ERa and
LKB1 expression were not altered nor were LKB1 and AMPK
phosphorylation compared with control (Fig. 2A). As shown in
Fig. 2B and C, Silencing ERa expression using tamoxifen and ERa
siRNA attenuated the effects of NDGA on LKB1 expression and LKB1,
AMPK phosphorylation (Fig. 2B,C). Furthermore, tamoxifen
obstructed the LKB1 translocation from nucleus to cytosol induced
by NDGA treatment (Fig. 2D). The results suggest that estrogenic
activity stimulates LKB1-mediated AMPK pathway, possibly
through ERa.
3.3. Estrogenic compound (NDGA) suppresses VSMC proliferation
stimulated by angiotensin II
To investigate whether cell proliferation is regulated by estro-
genic compound (NDGA) through an ERa-dependent pathway, we
examined the effect of inhibiting ERa on cell proliferation. NDGA
decreased VSMC proliferation induced by Ang II in a dose-
dependent manner (Fig. 3A). Tamoxifen reduced the NDGA-
mediated inhibition of VSMC proliferation (Fig. 3B). Geneticexpression. (A) AMPK phosphorylation at Thr172 (p-AMPK), LKB1 phosphorylation at
densitometric analysis. VSMCs were incubated with different concentrations of NDGA
periods (0, 1, 6, and 12 h). (C and D) The bar graphs below are arbitrary unit analysis of
rsus control.
Fig. 2. Effect of NDGA as an estrogenic compound. (A) AMPK phosphorylation at Thr172 (p-AMPK), LKB1 phosphorylation at Ser428 (p-LKB1), LKB1 expression and ERa expression
were determined by Western blot. VSMCs were treated with E2, E3 and DHT (1, 10 nM) for 1 h. V (vehicle) is 0.1% DMSO in culture medium. (B) VSMCs were transfected with ERa
siRNA for 3 days before treatment with NDGA and E2. (C) VSMCs were treated with tamoxifen 1 h before treatment with NDGA and E2. (D) Cells were doubly stained with To-pro-3
(red) and phosphorylated LKB1 (green). Yellow staining indicates the co-localization of nuclei and p-LKB1. All photographs were taken under confocal laser-scanning microscopy.
Values are means ± S.E.M from 5 independent measurements. *p < 0.05 versus control, #p < 0.05 versus Con siRNA and yp < 0.05 versus NDGA, E2.
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inhibition of VSMC proliferaiton (Fig. 3C). The protein expression
level of proliferating cell nuclear antigen (PCNA) also decreasedFig. 3. Effect of estrogenic activity on VSMC proliferation. (A) VSMCs were stimulated with 1
before NDGA treatment during stimulation with Ang II for 24 h (C) ERa siRNA was transfecte
before NDGA treatment in the presence of Ang II. ERa siRNA was transfected 3 days before t
blot analysis. Cell proliferation was detected by MTT analysis; Values are means ± S.E.M fro
yp < 0.05 versus Ang II þ NDGA, Con siRNA.with NDGA and was recovered by tamoxifen and ERa siRNA
(Fig. 3D). These results indicate that NDGA-induced ERa activation
inhibits VSMC proliferation.mM Ang II for 24 h and then NDGAwas added. (B) Cells were treated with tamoxifen 1 h
d 3 days before treatment with Ang II and NDGA. VSMCs treated with tamoxifen for 1 h
reatment with Ang II and NDGA. (D) PCNA protein expression was detected by western
m 5 independent measurements. *p < 0.05 versus control, #p < 0.05 versus Ang II and
Fig. 4. Estrogenic compound (NDGA)-induced AMPK activation is dependent on LKB1. Cells were stimulated with Ang II for 24 h and then transfected with control (Con) siRNA or
LKB1 siRNA in the presence of NDGA (25 mM). (A) Cell proliferation was determined by the MTT assay. (B) Protein expression of ERa, p-LKB1, LKB1, p-AMPK and p-ACC was
determined by western blot analysis. (C) Growth activity of VSMCs detected by colony forming assay. Viable colonies were ﬁxed and stained with crystal violet. After washing, the
stain absorbed by the cells was dissolved in 10% SDS solution and quantiﬁed by absorbance at 570 nm. (D) Protein expression of PCNA was determined by western blot analysis.
Values are means ± S.E.M from 5 independent measurements. *p < 0.05 versus control, #p < 0.05 versus Ang II and yp < 0.05 versus Con siRNA.
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inhibited by estrogenic activity
To determine whether LKB1 is required for NDGA-induced
AMPK activation, we investigated the effects of LKB1 siRNA on
NDGA-induced AMPK activation. Genetic inhibition of LKB1 with
siRNA reversed the NDGA-induced anti-proliferative effect
(Fig. 4A). NDGA-induced LKB1 and AMPK phosphorylation was
signiﬁcantly inhibited by pretreatment with LKB1 siRNA (Fig. 4B).
Moreover, NDGA-induced ERa in VSMCs was inhibited by pre-
treatment with LKB1 siRNA. We also performed a colony forming
assay. After staining, we found that colony formation was signiﬁ-
cantly lower in the Ang II þ NDGA group compared to the Ang II
group. In addition, colonies in VSMCs transfected with LKB1 siRNA
were signiﬁcantly increased compared to those with control siRNA
(Fig. 4C). The protein expression level of proliferating cell nuclear
antigen (PCNA)was also decreased byNDGA and recovered by LKB1
siRNA (Fig. 4D). These data show that estrogenic activity inhibits
Ang II-induced cell proliferation through LKB1 activation.3.5. Angiotensin II-induced cell cycle progression in G2/M phase is
reversed by estrogenic activity
To assess whether reduced cell proliferation was due to cell
cycle arrest, we veriﬁed the protein levels of p53, p27 and p21 by
western blot analysis and G0/G1 cell arrest by FACS analysis. Es-
trogenic compounds (NDGA) elevated p53, p27 and p21 protein
expression. p53, p27 and p21 are increased by NDGA-induced
AMPK activation. However, protein expression of p53, p27 and
p21 was decreased by the ER-antagonist using tamoxifen and ERa
siRNA (Fig. 5A,B). NDGA also inhibited cell cycle progression. The
rate of cells in G0/G1 phase was increased by NDGA. Thisphenomenon was attenuated after treatment with tamoxifen
(Fig. 5C,D). In contrast, the rate of cells in S- and G2/M- phases was
decreased by NDGA and recovered by tamoxifen. Thus, NDGA-
induced ERa expression participates in inhibition of cell prolifera-
tion derived by cell cycle arrest.
3.6. LKB1 inﬂuences ERa expression in VSMCs
To elucidate the speciﬁc mechanism between ERa and LKB1, we
measured ERa expression in the absence of LKB1. VSMCs were
transfected with control siRNA and LKB1 siRNA for 48 h before
being stimulated with NDGA. ERa expression was not upregulated
by NDGA in the absence of LKB1 (Fig. 6A). In A549 cells, a LKB1-
deﬁcient lung cancer cell line, did not express ERa protein despite
NDGA treatment (Fig. 6B). We conﬁrmed ERa expression by
immunoﬂuorescence analysis. As a result, ERa expression increased
overall in VSMCs treated with NDGA. In contrast, ERa expression
was signiﬁcantly attenuated by NDGA in cell membrane and cytosol
of A549 cells (Fig. 6C,D). Thus, estrogenic compound, NDGA stim-
ulates interaction between ERa and LKB1 (see Fig. 7).
4. Discussion
In the present study, we found that estrogenic activity regulates
VSMC proliferation through interaction between LKB1 and ERa. It
was previously asserted that ER stimulation by E2 activates AMPK
and could participate in the vasoprotective effect (23,24). However,
the upstream kinase of AMPK activated by E2 had not been iden-
tiﬁed yet.
We investigated the phytoestrogenic activity of NDGA and
whether this activity could regulate cell proliferation through
AMPK upstream kinase. Recent studies have demonstrated that
Fig. 5. Estrogenic compound (NDGA)-induced expression of p53, p27 and p21 inhibits cell cycle progression. (A, B) VSMC were stimulated with Ang II for 24 h and then treated with
tamoxifen 1 h before NDGA treatment. ERa siRNAwas transfected 3 days before the treatments with Ang II and NDGA. p53, p27 and p21 protein expression was detected by western
blot analysis. (C, D) Cell cycle progression was examined by FACS analysis. Values are means ± S.E.M from 5 independent measurements. *p < 0.05 versus control, #p < 0.05 versus
Ang II and yp < 0.05 versus Ang II þ NDGA, Con siRNA.
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potency in estrogen-responsive growth assay and ERE reporter
assay (25). We investigated whether NDGA could activate AMPKFig. 6. Role of estrogenic activity in the interaction between ERa and LKB1. (A) VSMCs were
AMPK phosphorylation at Thr172 (p-AMPK), LKB1 phosphorylation at Ser428 (p-LKB1), LKB1
treated with NDGA for 1 h. AMPK phosphorylation at Thr172 (p-AMPK), LKB1 phosphory
Western blot. (C, D) VSMCs and A549 cells were treated with NDGA. Cells were doubly stain
nuclei and ERa. All photographs were taken under confocal laser-scanning microscopy. Valuand its upstream kinases. LKB1 was phosphorylated in response to
NDGA, but another upstream kinase CaMKKbwas not affected (data
not shown).transfected with LKB1 and control (Con) siRNA 3 days before NDGA and E2 treatment.
expression and ERa expression were determined by Western blot. (B) A549 cells were
lation at Ser428 (p-LKB1), LKB1 expression and ERa expression were determined by
ed with To-pro-3 (red) and ERa (green). Yellow staining indicates the co-localization of
es are means ± S.E.M from 5 independent measurements. yp < 0.05 versus Con siRNA.
Fig. 7. Estrogenic compound (NDGA, E2) decreased angiotensin II-induced VSMC proliferation through estrogen receptor a/LKB1-AMPK activation pathway.
S.A. Kim et al. / Journal of Pharmacological Sciences 132 (2016) 78e8584Interestingly, NDGA elevated LKB1 phosphorylation as well as
LKB1 expression. We conﬁrmed that the estrogenic effect of NDGA
increased ERa protein expression and its expression was decreased
in the ER-antagonist using tamoxifen and ERa siRNA. These results
are the same as those in E2-and E3-treated VSMC. NDGA is reported
to increase stability that induce increased expression irrespective of
gene expression (12). Moreover, we suggest that inhibition of ERa
expression regulates LKB1 phosphorylation and expression as well.
Hence, the speciﬁc interactions between ERa and LKB1 in VSMCs
should be researched in further studies. Several studies revealed
that E2 and ERa-speciﬁc agonist PPT increased LKB1 mRNA
expression due to E2 binding putative EREs (26). However, our
study veriﬁed that alteration of LKB1 expression is caused by
regulation of translation not transcription. The LKB1 mRNA level
also was not changed by NDGA treatment (Supplement).
We found that LKB1 phosphorylation and expression was
regulated by ERa in VSMCs. In the absence of ERa, LKB1 and its
downstream AMPK and ACC phosphorylation was signiﬁcantly
reduced. The cellular location of LKB1 also changed: NDGA induced
LKB1 translocation from nucleus to cytosol. However, tamoxifen
blocked the translocation. The data indicate that inhibition of ERa
expression could affect both LKB1 activation and expression.
Some estrogenic compounds have been reported to modulate
cell proliferation and apoptosis through various mechanisms
(27e29). Generally, lignans and isoﬂavones are candidates as
antiproliferative or anticancer agents (30, 31). Our data also indi-
cate that NDGA reduces Ang II-induced VSMC proliferation.
Furthermore, NDGA induces G0/G1 cell cycle arrest via ERa-
dependent pathway.
Estrogen is known to have membrane effects independent of
steroid hormone (32,33). In the present study, we identiﬁed the
ERa location in VSMCs. ERa exists throughout the cell, including inthe nucleus and cytosol as well as the cell membrane. We
conﬁrmed that the enhanced cytosolic localization of ERa is due to
estrogenic activity-stimulated LKB1 activation in VSMCs.
Numerous studies have demonstrated the vasoprotective effects
of estrogens. Despite the beneﬁcial effects of hormone replacement
therapy, it is not a therapeutic option for cardiovascular disease
protection. Our ﬁndings suggest the involvement of LKB1 in NDGA-
induced ERa expression and inhibition of VSMC proliferation. Taken
together, the beneﬁcial effects of estrogenic compound (NDGA) on
inhibition of VSMC proliferation are mediated by interaction be-
tween ERa and LKB1, suggesting a potential mechanism for females
having less cardiovascular disease.Conﬂicts of interest
None of the authors have any conﬂicts of interest associated
with this study.Acknowledgments
This work was supported by the Medical Research Center Pro-
gram (2015R1A5A2009124) through the National Research Foun-
dation of Korea (NRF) funded by the Ministry of Science, ICT and
Future Planning.Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.jphs.2016.09.001.
S.A. Kim et al. / Journal of Pharmacological Sciences 132 (2016) 78e85 85References
(1) Lim Y, Kwon JS, Kim DW, Lee SH, Park RK, Lee JJ, et al. Obovatol fromMagnolia
obovata inhibits vascular smooth muscle cell proliferation and intimal hy-
perplasia by inducing p21cip1. Atherosclerosis. 2010;210:372e380.
(2) Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and
vascular function. Cardiovasc Res. 2002;53:605e619.
(3) Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension.
Cardiovasc Res. 2002;53:688e708.
(4) Yang XP, Reckelhoff JF. Estrogen, hormonal replacement therapy and cardio-
vascular disease. Curr Opin Nephrol Hypertens. 2011;20:133e138.
(5) Miller AP, Xing D, Feng W, Fintel M, Chen YF, Oparil S. Aged rats lose vaso-
protective and anti-inﬂammatory actions of estrogen in injured arteries.
Menopause. 2007;14:251e260.
(6) Masood DE, Roach EC, Beauregard KG, Khalil RA. Impact of sex hormone
metabolism on the vascular effects of menopausal hormone therapy in car-
diovascular disease. Curr Drug Metab. 2010;11:693e714.
(7) Sivritas D, Becher MU, Ebrahimian T, Arfa O, Rapp S, Bohner A, et al. Anti-
proliferative effect of estrogen in vascular smooth muscle cells is mediated by
kruppel-like factor-4 and manganese superoxide dismutase. Basic Res Cardiol.
2011;106:563e575.
(8) Arteaga S, Andrade-Cetto A, Cardenas R. Larrea tridentata (Creosote bush), an
abundant plant of Mexican and US-American deserts and its metabolite
nordihydroguaiaretic acid. J Ethnopharmacol. 2005;98:231e239.
(9) Siddique YH, Gulshan A, Tanveer B, Mohammad A. Protective role of nordi-
hydroguaiaretic acid (NDGA) against the genotoxic damage induced by
ethynodiol diacetate in human lymphocytes in vitro. J Environ Biol. 2007;28:
279e282.
(10) Martins S, Teixeira JA, Mussatto SI. Bioactive compounds (phytoestrogens)
recovery from Larrea tridentata leaves by solvents extraction. Sep Purif
Technol. 2012;88:163e167.
(11) Sathyamoorthy N, Wang TT, Phang JM. Stimulation of pS2 expression by diet-
derived compounds. Cancer Res. 1994;54:957e961.
(12) X1 Lü, Zhai W, Zhou Y, Zhou Y, Zhang H, Chang J. Crosslinking effect of
Nordihydroguaiaretic acid (NDGA) on decellularized heart valve scaffold for
tissue engineering. J Mater Sci Mater Med. 2010;21:473e480.
(13) Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that
maintains energy homeostasis. Nat Rev Mol Cell. 2012;13:251e262.
(14) Inoki K, Kim J, Guan KL. AMPK and mTOR in cellular energy homeostasis and
drug targets. Annu Rev Pharmacol Toxicol. 2012;52:381e400.
(15) Nagata D, Takeda R, Sata M, Satonaka H, Suzuki E, Nagano T, et al. AMP-
activated protein kinase inhibits angiotensin II-stimulated vascular smooth
muscle cell proliferation. Circulation. 2004;110:444e451.
(16) Lee MS, Kim D, Jo K, Hwang JK. Norhydroguaiaretic acid protects against high-
fat diet-induced fatty liver by activating AMP-activated protein kinase in
obese mice. Biochem Biophys Res Commun. 2010;401:92e97.
(17) Lipovka Y, Chen H, Vagner J, Price TJ, Tsao TS, Konhilas JP. Oestrogen receptors
interact with the a-catalytic subunit of AMP-activated protein kinase. Biosci
Rep. 2015;35:1e13.(18) Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D, et al.
LKB1 is the upstream kinase in the AMP-activated protein kinase cascade.
Curr Biol. 2003;13:2004e2008.
(19) Woods A, Dickerson K, Heath R, Hong SP, Momcilovic M, Johnstone SR,
et al. Ca2þ/calmodulindependent protein kinase kinase-beta acts upstream
of AMP-activated protein kinase in mammalian cells. Cell Metab. 2005;2:
21e33.
(20) McInnes KJ, Brown KA, Hunger NI, Simpson ER. Regulation of LKB1 expression
by sex hormones in adipocytes. Int J Obes (Lond). 2012;36:982e985.
(21) Nath-Sain S, Marignani PA. LKB1 catalytic activity contributes to estrogen
receptor a signaling. Mol Biol Cell. 2009;20:2785e2795.
(22) Chen HY, Wang JP, Santen RJ, Yue W. Adenosine monophosphate activated
protein kinase (AMPK), a mediator of estradiol-induced apoptosis in long-
term estrogen deprived breast cancer cells. Apoptosis. 2015;20:821e830.
(23) Gayard M, Guilluy C, Rousselle A, Viollet B, Henrion D, Pacaud P, et al. AMPK
alpha1-induced RhoA phosphorylation mediates vasoprotective effect of
estradiol. Arterioscler Thromb Vasc Biol. 2011;31:2634e2642.
(24) Kim JY, Jo KJ, Kim BJ, Baik HW, Lee SK. 17b-estradiol induces an interaction
between adenosine monophosphate-activated protein kinase and the in-
sulin signaling pathway in 3T3-L1 adipocytes. Int J Mol Med. 2012;30:
979e985.
(25) Fujimoto N, Kohta R, Kitamura S. Estrogenic activity of an antioxidant, nor-
dihydroguaiaretic acid (NDGA). Life Sci. 2004;74:1417e1425.
(26) Linher-Melville K, Zantinge S, Singh G. Liver kinase B1 expression (LKB1) is
repressed by estrogen receptor alpha (ERa) in MCF-7 human breast cancer
cells. BBRC. 2012;417:1063e1068.
(27) Plaza C, Pavani M, Faundez M, Maya JD, Morello A, Becker MI, et al. Inhibitory
effect of nordihydroguaiaretic acid and its tetra-acetylated derivative on
respiration and growth of adenocarcinoma TA3 and its multiresistant variant
TA3MTX-R. In Vivo. 2008;22:353e361.
(28) Ryan CJ, Zavodovskaya M, Youngren JF, Campbell M, Diamond M, Jones J, et al.
Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF-1 receptor
and androgen dependent growth of LAPC-4 prostate cancer cells. Prostate.
2008;68:1232e1240.
(29) Saeed IA, Ali L, Jabeen A, Khasawneh M, Rizvi TA, Ashraf SS. Estrogenic ac-
tivities of ten medicinal herbs from the Middle East. J Chromatogr Sci.
2013;51:33e39.
(30) Li HQ, Luo Y, Qiao CH. The mechanisms of anticancer agents by genistein
and synthetic derivatives of isoﬂavone. Mini Rev Med Chem. 2012;12:
350e362.
(31) McDonald RW, Bunjobpon W, Liu T, Fessler S, Pardo OE, Freer IK, et al. Syn-
thesis and anticancer activity of nordihydroguaiaretic acid (NDGA) and ana-
logues. Anticancer Drug Des. 2001;16:261e270.
(32) Farach-Carson MC, Davis PJ. Steroid hormone interactions with target cells:
cross talk between membrane and nuclear pathways. J Pharmacol Exp Ther.
2003;307:839e845.
(33) Takeda-Matsubara Y, Nakagami H, Iwai M, Cui TX, Shiuchi T, Akishita M, et al.
Estrogen activates phosphatases and antagonizes growth-promoting effect of
angiotensin II. Hypertension. 2002;39:41e45.
